An analgesic role for cannabinoids

---

• 1.
• British Medical Association. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers, 1997.
• 2.
• Grotenhermen F, Russo E. Cannabis and cannabinoids -- pharmacology, toxicology and therapeutic potential. New York: Haworth Press. In press.
• 3.
• Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995; 35: 607-634.
• 4.
• House of Lords Select Committee on Science and Technology. Cannabis: the scientific and medical evidence. HL Paper 151. London: The Stationery Office, 1998. Available at <http://www.parliament.the-stationery-office.co.uk/pa/ ld199798/ldselect/ldsctech/151/15101.htm>.
• 5.
• National Institutes of Health. Report on the medical uses of marijuana. 1997. <www.nih.gov/news/medmarijuana/MedicalMarijuana.htm>. Accessed 24 July 2000.
• 6.
• Devane WA, Dysarz FA 3d, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613.
• 7.
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
• 8.
• Beltramo M, Stella N, Calignano A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277: 1094-1097.
• 9.
• Jaggar SI, Hasnie FS, Sellaturay S, et al. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76: 189-199.
• 10.
• Bian D, Nichols ML, Ossipov MH, et al. Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. Neuroreport 1995; 6: 1981-1984.
• 11.
• Mao J, Price DD, Lu J, et al. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett 2000; 280: 13-16.
• 12.
• National Health and Medical Research Council. Acute pain management scientific evidence. Canberra: NHMRC, 1999.
• 13.
• Ashton CH. Biomedical benefits of cannabinoids? Addiction Biol 1999; 4: 111-126.
• 14.
• Noyes R Jr, Brunk SF, Avery DAH, et al. The analgesic properties of delta- 9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18: 84-89.
• 15.
• Staquet M, Gantt C, Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397-401.
• 16.
• Jain AK, Ryan JR, McMahon FG, et al. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21: 320S-326S.
• 17.
• Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52: 483-486.
• 18.
• Hill SY, Schwin R, Goodwin DW, Powell BJ. Marihuana and pain. J Pharmacol Exp Ther 1974; 188: 415-418.
• 19.
• Raft D, Gregg J, Ghia J, et al. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. Clin Pharmacol Ther 1977; 21: 26-33.
• 20.
• Chesher GB, Christie MJ, Morgan JP. Science signals a new understanding of marihuana. Drug Alcohol Rev 1994; 13: 307-317.
• 21.
• Joy JE, Watson SJ, Benson JA, editors. Marijuana and medicine: assessing the science base. Washington, DC: National Academy Press, 1999.
• 22.
• Gowing LR, Ali RL, Christie P, et al. Therapeutic use of cannabis: clarifying the debate. Drug Alcohol Rev 1998; 17: 445-452.
• 23.
• Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use. National Drug Strategy Monograph Series No. 25. Canberra: AGPS, 1994.
• 24.
• Beautrais AL, Joyce PR, Mulder RT. Cannabis abuse and serious suicide attempts. Addiction 1999; 94: 1155-1164.
• 25.
• ⁹-(trans)-tetrahydrocannabinol] in sesame oil and encapsulated in soft gelatin capsules from Schedule II to Schedule III. (Doc. 99-16833) Federal Register 1999; 64(127): 35928-35930. Available at <http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=1999_ register&docid=99-16833-filed>.